Current immunotherapy approaches often result in partial immunity that predisposes the patient to a risk of reinfection or serious toxicity issues. In Singh Lab, we focus on developing nano-engineered technologies to modulate immune cells and program them for cancer immunotherapy.
To that end, we have engineered a self-assembly protein-biomaterial nanogel system for inducing robust immunity at low protein doses. Our more recently funded project with Prof. Brian Rudd at Cornell Immunology focuses on developing nanoneedles for cancer immunotherapy.
